Bayer Net Income/Loss 2010-2024 | BAYRY
Bayer annual/quarterly net income/loss history and growth rate from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Bayer net income/loss for the quarter ending December 31, 2024 was $-2.755B, a 13.48% decline year-over-year.
- Bayer net income/loss for the twelve months ending December 31, 2024 was $-0.892B, a 82.79% decline year-over-year.
- Bayer annual net income/loss for 2024 was $-2.755B, a 13.48% decline from 2023.
- Bayer annual net income/loss for 2023 was $-3.184B, a 172.54% decline from 2022.
- Bayer annual net income/loss for 2022 was $4.389B, a 263.01% increase from 2021.
Bayer Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$-2,755 |
| 2023 |
$-3,184 |
| 2022 |
$4,389 |
| 2021 |
$1,209 |
| 2020 |
$-17,775 |
| 2019 |
$2,722 |
| 2018 |
$2,021 |
| 2017 |
$3,671 |
| 2016 |
$5,044 |
| 2015 |
$4,462 |
| 2014 |
$4,577 |
| 2013 |
$4,232 |
| 2012 |
$3,210 |
| 2011 |
$3,443 |
| 2010 |
$1,740 |
| 2009 |
$1,895 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$25.032B |
$50.438B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
